Push vs. Pull: Finding Better Ways to Incentivize Development of Antibiotics

There's an excellent, balanced summary of the pros and cons of "push" and "pull" forms of incentivizing drug development (focused on antibiotics), by Kurt Karst on the FDA Law Blog. Karst quotes and links to a London School of Economics paper that urges governments to take more proactive roles in working with industry to establish viable incentives for those who develop promising antibiotic medicines, in light of "superbugs" and the issue of resistance to current antibiotics.

The report itself is exhaustive but worth a look. Don't be put off by the "Confidential" label at the bottom of each page, since the PDF is easily found in many places on the web.